Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Yao, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
- Baylor College of MedicineResidency, Internal Medicine, 1995 - 1998
- Baylor College of MedicineClass of 1995
Certifications & Licensure
- FL State Medical License 2021 - Present
- TN State Medical License 2023 - 2027
- GA State Medical License 2023 - 2026
- LA State Medical License 2023 - 2026
- OK State Medical License 2020 - 2026
- OK State Medical License 2020 - 2026
- WA State Medical License 2023 - 2026
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.Van K Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad
Clinical Cancer Research. 2025-05-01 - 1 citationsHealth-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.Alberto Sobrero, Arvind Dasari, Jeneth Aquino, Sara Lonardi, Rocio Garcia-Carbonero
European Journal of Cancer. 2025-03-11 - 1 citationsClassification of Gastric Neuroendocrine Tumors and Associations With Survival.Yun Song, Eunise Chen, Yi-Ju Chiang, James C Yao, Daniel M Halperin
Journal of Surgical Oncology. 2025-02-01
Press Mentions
- 10 Things to Know About Neuroendocrine TumorsFebruary 23rd, 2024
- HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary OfSeptember 8th, 2022
- Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-Ep Phase III Trial at ESMO Annual MeetingSeptember 25th, 2019
- Join now to see all